Close Menu

NEW YORK (GenomeWeb) – NeoGenomics today reported a 25 percent year-over-year jump in its Q4 revenues, buoyed by its recently completed acquisition of Genoptix.

The cancer genetic testing company reported revenues of $76.5 million for the three-month period ended Dec. 31, 2018, up from restated revenues of $61.4 million in the same period last year. The consensus Wall Street estimate was $71.4 million.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Oct
03

This webinar will provide an overview of how an international reference laboratory has implemented an automated next-generation sequencing workflow with custom panels for analyzing cancer samples.

Oct
10

This webinar will provide an overview of how a pathology laboratory validated a 77-gene next-generation sequencing-based liquid biopsy assay.